INSIGHT 01Fact
89%
89% of applications are in Pharmaceuticals
1,147 applications in this field, 1,095 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
Company patentsInnovative medicines and biopharmaceuticals
COMPANY PATENT INTELLIGENCE
Explore medicines, formulations and related technologies through publications attributed to selected Novartis legal entities.
≥1,371docs
114 per month · peak 2025-03 (196)
Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.
INSIGHT 01Fact
89%
1,147 applications in this field, 1,095 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
1,286 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.
Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.
This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.
| Technology field | 25-01 | 25-02 | 25-03 | 25-04 | 25-05 | 25-06 | 25-07 | 25-08 | 25-09 | 25-10 | 25-11 | 25-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 117 | 87 | 176 | 96 | 97 | 95 | 87 | 85 | 101 | 107 | 65 | 85 |
| Biotechnology | 52 | 39 | 60 | 43 | 42 | 33 | 43 | 27 | 45 | 30 | 28 | 38 |
| Organic fine chemistry | 45 | 22 | 68 | 22 | 30 | 36 | 36 | 31 | 31 | 42 | 25 | 32 |
| Medical technology | 9 | 10 | 7 | 11 | 10 | 4 | 11 | 8 | 11 | 7 | 4 | 9 |
| Analysis of biological materials | 3 | 6 | 10 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 2 | 3 |
| Basic materials chemistry | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 4 | 1 | 1 | 0 | 0 |
| Chemical engineering | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 |
| Measurement | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.
Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.
Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.
Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.
Position 3 of 26 published companies.
Method: Sum of squared field shares
Position 9 of 26 published companies.
Method: Utility model documents ÷ all documents
The source has no CPC codes, so this cannot be computed.
Method: Documents with CPC Y02 ÷ documents with CPC
Position 19 of 26 published companies.
Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications
Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.
Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.
Review the entity listEntity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.
Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.
Showing 1 of 1 entities
官方年报确认 Novartis AG 为控股法人;仅纳入其来源标准名,不将 Novartis Pharma AG 等独立法人作为别名。
Review evidenceRelationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.
Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.
Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.
Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.
Showing 2 sample patents · 0 linked observations
Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.
US20250000973A1
The abstract concerns making CAR-expressing immune effector cells. Claim 1 combines treatment with a multispecific molecule having CD3 and costimulatory binding domains plus specified Fc mutations, introduction of CAR-encoding nucleic acid, and cell harvest. It includes alternative timing or limited-expansion conditions. The focus is the constrained manufacturing process, not every CAR-cell product.
US20250011428A1
The abstract discusses engineered IgG Fc effects on effector function, receptor binding and stability. Claim 1 specifically requires an immunoglobulin or fragment with one or more antigen-binding domains, a cysteine substitution at EU position 235 in the Fc variant, and reduced effector functions relative to wild type. Other abstract properties are not all limitations of this claim.
50 publication offices · 1,371 documents
Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.
Invention publication
Subcutaneous administration and dosing method of olanzapine for use in the treatment of depressive disorders
NOVARTIS AG
Pharmaceuticals
Invention publication
Compositions and methods for selective protein degradation
NOVARTIS AG
BiotechnologyPharmaceuticals
Other
Dosage regimen for a s1p receptor agonist
NOVARTIS AG
Pharmaceuticals
Other
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
NOVARTIS AG
Pharmaceuticals
Other
Combinations of fgfr4 inhibitors and bile acid sequestrants
NOVARTIS AG
Pharmaceuticals
Other
Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
NOVARTIS AG
Organic fine chemistryPharmaceuticals
Invention grant
Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
NOVARTIS AG
Organic fine chemistryPharmaceuticals
Invention grant
Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
NOVARTIS AG
Organic fine chemistryPharmaceuticals
Invention grant
Pyrazolopyridine derivatives and uses thereof
NOVARTIS AG
Organic fine chemistryPharmaceuticals
Invention grant
Antibody molecules to LAG-3 and uses thereof
NOVARTIS AG / IMMUTEP SAS
BiotechnologyPharmaceuticals
Other
Methods of making chimeric antigen receptor -expressing cells
NOVARTIS AG / UNIV PENNSYLVANIA
BiotechnologyPharmaceuticals
Other
Complement factor b inhibitor and pharmaceutical composition, preparation method and use thereof
NOVARTIS AG
Organic fine chemistryPharmaceuticals
Other
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
NOVARTIS AG
BiotechnologyPharmaceuticals
Invention publication
Antibody drug conjugates with linkers comprising hydrophilic groups
NOVARTIS AG
BiotechnologyPharmaceuticals
Invention publication
Antibody drug conjugates with linkers comprising hydrophilic groups
NOVARTIS AG
BiotechnologyPharmaceuticals
Invention publication
Natriuretic peptide receptor 1 antibodies and methods of use
NOVARTIS AG
BiotechnologyPharmaceuticals
Invention publication
Methods of treating giant cell arteritis using interleukin-17 (IL-17) antagonists
NOVARTIS AG / UNIV FREIBURG ALBERT LUDWIGS
BiotechnologyPharmaceuticals
Other
New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
NOVARTIS AG
Pharmaceuticals
Other
ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
NOVARTIS AG
BiotechnologyPharmaceuticals
Other
1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
NOVARTIS AG
Organic fine chemistryPharmaceuticals
Titles come from the source bibliography. Select a number to read the full document on this site.
Upload your invention disclosure and get an editable draft that follows CNIPA practice.
Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.
Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.
These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.
The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.
Novartis AG
Configured aliases: NOVARTIS AG
Original review note: 官方年报确认 Novartis AG 为控股法人;仅纳入其来源标准名,不将 Novartis Pharma AG 等独立法人作为别名。
Review evidenceFound a wrong attribution or number? Tell us